Management of Bradycardia and Dizziness in Untreated Hypothyroidism
Treat the hypothyroidism first with levothyroxine replacement therapy rather than pursuing cardiac interventions, as bradycardia and dizziness from hypothyroidism are reversible conditions that respond well to thyroid hormone replacement. 1
Primary Treatment Approach
The 2018 ACC/AHA/HRS bradycardia guidelines explicitly state that patients with symptomatic bradycardia secondary to reversible causes should first be managed by directing therapy at eliminating or mitigating the offending condition (Class I recommendation). 1 Hypothyroidism is specifically identified as a reversible cause that can produce clinically significant bradycardia, and cardiovascular abnormalities respond well to thyroxine (T4) replacement therapy. 1
Initiate Thyroid Hormone Replacement
Start levothyroxine at 12.5–25 µg/day in patients with known coronary heart disease to reduce the risk of precipitating angina or cardiac events, compared with the standard 50 µg/day start in younger adults without cardiac disease. 2
For patients without known cardiac disease, standard dosing can be initiated, but monitor closely for cardiac symptoms during titration. 2
Check for adrenal insufficiency before starting levothyroxine, as glucocorticoid replacement must be established first to prevent acute adrenal crisis caused by increased glucocorticoid clearance. 2
Expected Clinical Response
Multiple case reports demonstrate complete resolution of bradycardia and syncope following thyroid hormone replacement in hypothyroid patients. 3, 4, 5
One case documented resolution of ventricular tachycardia storm and cardiogenic shock with initiation of T3 and T4 replacement in profound hypothyroidism. 6
Treatment of hypothyroidism led to complete symptom resolution in patients presenting with bradyarrhythmia and syncopal attacks. 3
What NOT to Do
Permanent pacemaker implantation should be avoided when bradycardia is attributable to untreated hypothyroidism. 1 The ACC/AHA/HRS guidelines emphasize that permanent pacing has no clinical benefit when symptoms occur due to reversible causes, and the procedure carries surgical risk and long-term lead management implications. 1
One case report describes how a planned permanent pacemaker was appropriately cancelled after good history-taking revealed hypothyroidism as the underlying cause of bradycardia. 4
Invasive therapeutic measures can be precluded by adequate management of endocrine issues. 4
Monitoring Strategy
Perform serial TSH measurements to maintain euthyroidism and guide dose titration while avoiding overtreatment. 2
Monitor heart rate response as thyroid function normalizes—there is currently no direct correlation established between TSH levels and heart rate to guide therapeutic management. 7
Reassess symptoms of dizziness and bradycardia as thyroid replacement takes effect, typically over weeks to months. 3, 5
Important Caveats
Avoid overtreatment with levothyroxine, as suppressing TSH to ≤0.1 mIU/L in patients ≥60 years triples the 10-year risk of atrial fibrillation. 2 Approximately 20% of elderly patients receiving levothyroxine experience some degree of overtreatment, highlighting the need for careful dose titration. 2
The early recognition and effective treatment of thyroid dysfunction in patients with arrhythmia is mandatory because the long-term prognosis may be improved with appropriate treatment. 8 Untreated hypothyroidism increases the risk of ventricular arrhythmias, while hyperthyroidism increases atrial arrhythmias. 8
When to Consider Cardiac Evaluation
If bradycardia and dizziness persist despite achieving euthyroid status with adequate thyroid replacement, then cardiac evaluation including ambulatory monitoring may be warranted to assess for intrinsic sinus node dysfunction. 1 However, this should only occur after the reversible cause (hypothyroidism) has been adequately treated and sufficient time allowed for cardiovascular recovery.